Organon & Co. (OGN) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Organon & Co. (OGN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Organon & Co. (OGN)

Company Performance

Current Price

as of Oct 18, 2024

$17.61

P/E Ratio

4.53

Market Cap

$4.53B

Description

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Metrics

Overview

HQJersey City, NJ
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerOGN
Price$17.61-0.17%

Trading Information

Market Cap$4.53B
Float99.78%
Average Daily Volume (1m)1,976,728
Average Daily Volume (3m)1,900,086
EPS$3.91

Company

Revenue$6.35B
Rev Growth (1yr)-0.06%
Net Income$195.00M
Gross Margin58.43%
EBITDA Margin28.13%
EBITDA$452.00M

EV$13.31B
EV/Revenue2.10
P/E4.53
P/S0.72
P/B31.49

Documents

Earnings Calls

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-11-02)

Earnings Report (2023-08-08)

Factset

Factset Business Description

Wikipedia

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Organon & Co. Q3 ($12.95, -1.71) (2023-11-02T16:15:28Z)

Samsung Bioepis & Organon announce FDA acceptance of sBLA for Interchangeability Designation for HADLIMA (adalimumab-bwwd) (2023-11-07T21:19:45Z)

organon & Lilly enter Commercialization agreement in Europe for two migraine medicines ($13.08, 0.00) (2023-12-18T12:34:33Z)

Organon & Co. reports Q3 EPS $0.87 ex-items vs FactSet $1.05 [8 est, $1.02-1.09] ($14.65, 0.00) (2023-11-02T11:36:18Z)

Organon & Co. downgraded to neutral from buy at Goldman Sachs ($13.11, 0.00) (2023-11-03T11:26:10Z)